2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.07C.16 Real-World Outcomes of Patients with Resectable Early-Stage Non-Small Cell Lung Cancer Treated with Neoadjuvant Chemoimmunotherapy

EP.07C.16 Real-World Outcomes of Patients with Resectable Early-Stage Non-Small Cell Lung Cancer Treated with Neoadjuvant Chemoimmunotherapy

Back to course

Pdf Summary

The study aimed to analyze the real-world outcomes of patients with early-stage resectable non-small cell lung cancer (NSCLC) treated with neoadjuvant chemoimmunotherapy, specifically using nivolumab and chemotherapy, following the Checkmate 816 study protocol. Conducted at Mayo Clinic sites, the retrospective analysis included patients with stage IB-IIIA NSCLC treated between March 2022 and December 2023. <br /><br />The study found that nivolumab in combination with chemotherapy improved pathological complete response (pCR), major pathological response (mPR), and event-free survival (EFS) compared to chemotherapy alone. Of the 26 patients analyzed, 54% achieved either major or complete pathological response (mPR or cPR). All patients underwent successful surgical resection via lobectomy, although there were two cases of severe post-operative complications leading to deaths. <br /><br />In terms of treatment specifics, most patients received carboplatin with either pemetrexed (69%), paclitaxel (23%), or gemcitabine (8%). Notably, 27% of patients experienced immunotherapy-related toxicity, some requiring hospitalization. Post-treatment, 19% of patients received adjuvant therapy involving nivolumab or targeted therapies. <br /><br />By the study's conclusion, 92% of patients were still alive, and the median EFS was not reached, indicating potential benefits in patient survival. The results corroborate previous findings from the Checkmate 816 study in supporting neoadjuvant chemoimmunotherapy's efficacy for treating early-stage resectable NSCLC in a real-world clinical setting.

Asset Subtitle

Antonious Hazim

Meta Tag

Speaker Antonious Hazim

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

NSCLC

neoadjuvant chemoimmunotherapy

nivolumab

pathological complete response

major pathological response

event-free survival

Checkmate 816

carboplatin

immunotherapy-related toxicity

adjuvant therapy